Thrombocytopenia: Difference between revisions
imported>Robert Badgett |
imported>Robert Badgett |
||
| Line 15: | Line 15: | ||
;Disseminated intravascular coagulation (DIC) | ;Disseminated intravascular coagulation (DIC) | ||
;Giant hemangiomas | ;Giant hemangiomas | ||
'''Microangiopathic hemolytic anemias (MAHAs)''' include [[thrombotic thrombocytopenia purpura]] (TTP) and [[hemolytic uremia syndrome]] (HUS). TTP is usually an inherited or acquired deficiency of | '''Microangiopathic hemolytic anemias (MAHAs)''' include [[thrombotic thrombocytopenia purpura]] (TTP) and [[hemolytic uremia syndrome]] (HUS). TTP is usually an inherited or acquired deficiency of von Willebrand factor (vWF) metalloprotease, also called ADAMTS 13. | ||
==Cause/etiology== | ==Cause/etiology== | ||
===Medications=== | ===Medications=== | ||
Revision as of 07:32, 11 January 2008
Thrombocytopenia is a decrease in the platelet count. The half-life of a platelet in a normal person is about 4 days.[1]
Classification
The following classification is proposed by Robbins and Cotran.[2]
Decreased production of platelets
Decreased survival of platelets
Immunolologic destruction
Autoimmune includes immune thrombocytopenia purpura or Werlhof's Disease. The chronic form in adults is usually caused by antibodies to Platelet glycoprotein GPIIb-IIIa complex or Ib-IX.[2]
- Isoimmune
- Drug associated
- Infections
Nonimmunolologic destruction
- Disseminated intravascular coagulation (DIC)
- Giant hemangiomas
Microangiopathic hemolytic anemias (MAHAs) include thrombotic thrombocytopenia purpura (TTP) and hemolytic uremia syndrome (HUS). TTP is usually an inherited or acquired deficiency of von Willebrand factor (vWF) metalloprotease, also called ADAMTS 13.
Cause/etiology
Medications
A systematic review has identified common causes of drug-induced thrombocytopenia.[3]
Drug-induced thrombocytopenia maybe immune medicated.[4] Heparin-induced thrombocytopenia (HIT) is caused by anti-platelet antibodies.[5] Other drugs include vancomycin [6] and oxaliplatin[7]
References
- ↑ Fritz E, Ludwig H, Scheithauer W, Sinzinger H (1986). "Shortened platelet half-life in multiple myeloma". Blood 68 (2): 514–20. PMID 3730614. [e]
- ↑ 2.0 2.1 Cotran, Ramzi S.; Kumar, Vinay; Fausto, Nelson; Nelso Fausto; Robbins, Stanley L.; Abbas, Abul K. (2005). Robbins and Cotran pathologic basis of disease. St. Louis, Mo: Elsevier Saunders. ISBN 0-7216-0187-1.
- ↑ George JN, Raskob GE, Shah SR, et al (1998). "Drug-induced thrombocytopenia: a systematic review of published case reports". Ann. Intern. Med. 129 (11): 886–90. PMID 9867731. [e]
- ↑ Aster RH, Bougie DW (2007). "Drug-induced immune thrombocytopenia". N. Engl. J. Med. 357 (6): 580–7. DOI:10.1056/NEJMra066469. PMID 17687133. Research Blogging.
- ↑ Arepally GM, Ortel TL (2006). "Clinical practice. Heparin-induced thrombocytopenia". N. Engl. J. Med. 355 (8): 809–17. DOI:10.1056/NEJMcp052967. PMID 16928996. Research Blogging.
- ↑ Von Drygalski A, Curtis BR, Bougie DW, et al (2007). "Vancomycin-induced immune thrombocytopenia". N. Engl. J. Med. 356 (9): 904–10. DOI:10.1056/NEJMoa065066. PMID 17329697. Research Blogging.
- ↑ Dold FG, Mitchell EP (2003). "Sudden-onset thrombocytopenia with oxaliplatin". Ann. Intern. Med. 139 (2): E156. PMID 12859182. [e]
External links
- University of Oklahoma Health Sciences Center's Platelets on the Web. This includes a database of reports of drug-induced thrombocytopenia.